AnserBio
- Biotech or pharma, therapeutic R&D
AnserBio is a preclinical stage company developing a p53 replacement therapy for a wide range of oncology indications. Proprietary extracellular vesicles are utilized as delivery vehicle.
AnserBio is actively looking for partnership opportunities.